Latest News and Press Releases

Larkspur Biosciences announced the first participant has been dosed in the Phase 1 clinical study of its lead candidate, LRK-4189, in healthy volunteers.

Pluristyx launches Organoid COMMONS, uniting 10 industry leaders to set global standards for human-relevant organoids and advance non-animal drug testing.

Pluristyx launches Organoid COMMONS, uniting 10 industry leaders to set global standards for human-relevant organoids and advance non-animal drug testing.

Dublin, Dec. 02, 2025 (GLOBE NEWSWIRE) -- The "Deep Learning Market in Drug Discovery and Diagnostics - Industry Trends and Global Forecasts to 2035: By Therapeutic Areas and Key Geographical...

Dublin, Nov. 26, 2025 (GLOBE NEWSWIRE) -- The "Antibody Collaboration and Licensing Deals 2019-2025" has been added to ResearchAndMarkets.com's offering.This report contains a comprehensive listing...

The Company expects to initiate first-in-human study in early 2026, with initial data anticipated H2 2026 Clinical Trial Application (CTA) submission marks the advancement of Tangram’s GalOmic RNAi...

Positive results from ianalumab pivotal Phase III trial in ITP patients previously treated with corticosteroids to be presented as late-breakerScemblix data across clinical and real-world settings...

Ad hoc announcement pursuant to Art. 53 LR Itvisma (onasemnogene abeparvovec-brve) demonstrated improved motor function and stabilization in patients regardless of SMA treatment history in Phase III...

Expansion represents significant investment in North Carolina and is expected to create 700 new jobs in the state by end of 2030Enables manufacturing of medicines across company’s main therapeutic...

Boston, Nov. 17, 2025 (GLOBE NEWSWIRE) -- According to the latest study from BCC Research, “Artificial Intelligence (AI) in Pharmaceuticals: Global Markets” is projected to grow from $3.8 billion in...